Results published in the peer-reviewed journal Investigational New Drugs Study in heavily pre-treated patients with solid ...

This review will focus on recent advances in our understanding of how these cells contribute to the tumor response to hypoxia in non-small-cell lung cancer ... cells is a microenvironment of ...

Patients with advanced non-small cell lung cancer (NSCLC) are often treated with immunotherapy drugs known as checkpoint inhibitors, which are designed to strengthen the immune system's ability to ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

Study Rationale and Design Lou explained that while immune checkpoint inhibitors and T cell-based therapies have been successful in non-small cell lung cancer and melanoma, "we have failed to see ...

Tumor-infiltrating lymphocytes (TILs) are a grouping of mostly T cells that enter tumors and elicit an initial immune response ... pivotal trial for non-small-cell lung cancer with lifileucel ...

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both ...

More information on all MD Anderson AACR Annual Meeting content can be found at MDAnderson.org/AACR. Targeted small molecule inhibitors may combat metastatic gastric cancer (Abstract 1186) Some ...